Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study to compare three year treatment outcomes of Ranibizumab and Aflibercept for Neovascular age-related macular degeneration using data from Fight retinal blindness registry

Next Previous
Trial Profile

A retrospective study to compare three year treatment outcomes of Ranibizumab and Aflibercept for Neovascular age-related macular degeneration using data from Fight retinal blindness registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms The Fight retinal blindness registry

Most Recent Events

  • 01 Jun 2022 Results(n=402) of retrospective analysis of naive diabetic macular edema eyes starting intravitreal injections of ranibizumab (0.5 mg) or aflibercept (2 mg) , published in the Retina
  • 06 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top